文献速递中毒与环境急症消化、代谢与肾脏急症

英国伯明翰入院多药使用者中检出N-去乙基异硝西泮

N-desethyl isotonitazene detected in polydrug users admitted to hospital in Birmingham, United Kingdom.
PubMed 文献 · Clin Toxicol (Phila) · 2024-02-14
一句话结论伯明翰入院药物滥用者中检出N-去乙基异硝西泮,多与其他物质混用,仅1例可单独归因于该药并需纳洛酮复苏。

本文为观察性病例系列,纳入2023年7月至10月Sandwell and West Birmingham National Health Service Trust所属医院收治的疑似或自述物质使用患者,毒物筛查均检出N-去乙基异硝西泮。共20次就诊、19例患者,19次就诊检出多种物质,最常见为可卡因及其主要代谢物苯甲酰爱康宁(19例),其次为吗啡(13例)、海洛因特异性代谢物6-单乙酰吗啡(11例)、赛拉嗪(10例)等;仅1例除N-去乙基异硝西泮外未检出其他物质,该例表现为昏迷、瞳孔缩小、呼吸过缓和高碳酸血症,对纳洛酮有反应。全血中位浓度1.53 µg/L(n=14,范围0.59-5.48),尿中位浓度27.75 µg/L(n=16,范围0.51-91.53)。作者认为需对非法药物市场开展毒物监测。

要点

  • 19例患者中仅1例除N-去乙基异硝西泮外未检出其他物质,该例表现为昏迷、瞳孔缩小、呼吸过缓和高碳酸血症,对纳洛酮有反应。
  • 20次就诊中19次检出多种物质:可卡因及其主要代谢物苯甲酰爱康宁19例、吗啡13例、6-单乙酰吗啡11例、赛拉嗪10例、加巴喷丁类8例、美沙酮和/或2-乙基-1,5-二甲基-3,3-二苯基吡咯烷7例、苯二氮䓬类6例、合成大麻素MDMB-4en-PINACA 5例。
  • 全血N-去乙基异硝西泮中位浓度1.53 µg/L(n=14,范围0.59-5.48),尿中位浓度27.75 µg/L(n=16,范围0.51-91.53)。
  • 作者指出,尽管多数患者表现符合阿片类药物过量的典型特征,但仅1例可将表现单独归因于N-去乙基异硝西泮毒性。
  • 作者认为随着物质滥用模式演变和新型精神活性物质不断出现,需对非法药物市场开展毒物监测。

适用人群与场景

  • 2023年7月至10月收治于Sandwell and West Birmingham National Health Service Trust所属医院、疑似或自述物质使用的患者,毒物筛查均检出N-去乙基异硝西泮。
  • 该队列患者均为二醋吗啡(海洛因)的 experienced users。

处置流程与药物剂量

  • 仅1例除N-去乙基异硝西泮外未检出其他物质,该例表现为昏迷、瞳孔缩小、呼吸过缓和高碳酸血症,对纳洛酮有反应。

红旗征与不能漏的情况

  • 昏迷、瞳孔缩小、呼吸过缓和高碳酸血症提示阿片类药物过量,该例对纳洛酮有反应。

研究设计与关键结果

  • 观察性病例系列,共20次就诊、19例患者毒物筛查N-去乙基异硝西泮阳性。
  • 19次就诊检出多种物质;仅1例除N-去乙基异硝西泮外未检出其他物质。
  • 其他检出物质例数:可卡因及其主要代谢物苯甲酰爱康宁19例、吗啡13例、6-单乙酰吗啡11例、赛拉嗪10例、加巴喷丁类(普瑞巴林和/或加巴喷丁)8例、美沙酮和/或2-乙基-1,5-二甲基-3,3-二苯基吡咯烷7例、苯二氮䓬类6例、合成大麻素MDMB-4en-PINACA 5例。
  • 全血N-去乙基异硝西泮中位浓度1.53 µg/L(n=14,范围0.59-5.48),尿中位浓度27.75 µg/L(n=16,范围0.51-91.53)。

证据类型、等级与局限

  • 观察性病例系列。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,本病例系列提示随着物质滥用模式演变和新型精神活性物质不断出现,需对非法药物市场开展毒物监测。
  • 作者指出,多数患者表现符合阿片类药物过量典型特征,但仅1例可将表现单独归因于N-去乙基异硝西泮毒性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Nitazenes are potent synthetic opioids and N-desethyl isotonitazene, a metabolite of isotonitazene, has emerged as a drug in its own right.

METHODS: This is an observational case series of patients with suspected or declared substance use who were admitted to hospitals in the Sandwell and West Birmingham National Health Service Trust between July and October 2023. All patients were found on toxicological screening to have been exposed to N-desethyl isotonitazene.

RESULTS: Twenty presentations involving 19 patients who tested positive for N-desethyl isotonitazene were included in the study. In 19 presentations, multiple substances were detected on toxicological screening. The number of patients testing positive for other substances were: 19 for cocaine and its main metabolite benzoylecgonine, 13 for morphine, 11 for the heroin-specific metabolite 6-monoacetylmorphine, ten for xylazine, eight for gabapentinoids (pregabalin and/or gabapentin), seven for methadone and/or the metabolite, 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine, six for benzodiazepines and five for the synthetic cannabinoid MDMB-4en-PINACA. Only one patient had no other substances detected apart from N-desethyl isotonitazene. This patient presented with coma, miosis, bradypnoea and hypercapnia and responded to naloxone. In this cohort, the median concentration of N-desethyl isotonitazene was 1.53 µg/L (n = 14; range 0.59-5.48) in whole blood and 27.75 µg/L (n = 16; range 0.51-91.53) in urine.

DISCUSSION: The majority of the patients in this cohort presented with features typical of an opioid overdose, which is unsurprising as they were all experienced users of diamorphine. Although these features are also consistent with the known effects of N-desethyl isotonitazene, in only one case is it possible to attribute the patient's features to N-desethyl isotonitazene toxicity alone.

CONCLUSIONS: This case series highlights the need for toxicovigilance in the illicit drug market as patterns of substance misuse evolve and novel psychoactive substances continue to emerge.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Pucci M, Singh Jutley G, Looms J, et al. N-desethyl isotonitazene detected in polydrug users admitted to hospital in Birmingham, United Kingdom. Clin Toxicol (Phila). 2024. PMID: 38353737. doi:10.1080/15563650.2024.2309321

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。